Previous 10 | Next 10 |
The following slide deck was published by Arrowhead Pharmaceuticals, Inc. in conjunction with this Read more ...
The following slide deck was published by Arrowhead Pharmaceuticals, Inc. in conjunction with this Read more ...
Arrowhead Pharmaceuticals (NASDAQ: ARWR ) announces positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III (APOC3) being developed as a treatment for patients with hypertriglyceridemia, and ARO-ANG3 targeting angiopoiet...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III (APOC3) being developed as a treatment for patients with hypertriglyceridemia, and ARO-...
Arrowhead Pharmaceuticals (NASDAQ: ARWR ) and collaboration partner/licensee Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ ) , announce positive data from the second part of a Phase 1/2 clinical trial evaluating RNAi therapeutic candidate JNJ-3989 (formerly ARO-H...
Data from Enanta Pharmaceuticals' (NASDAQ: ENTA ) development programs for non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV) will be virtually presented at the European Association for the Study of the Liver Annual Meeting. More news on: Enanta Pharmaceuticals, Inc....
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of Phase 2 clinical data from the AROHBV1001 phase 1/2 study on a double combination of JNJ-3989 (formerly ARO-HBV) and a nucleos(t)ide analog (NA) with collaborator Janssen Pharmaceuticals, Inc., part of the Janss...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: The Digital International Liver Congress - The Annual Meeting of the European Association for the Study of the Liver (EASL) – August 27-29, 2020 ...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear...
News, Short Squeeze, Breakout and More Instantly...
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
- Expanded Access Program initiated to make investigational plozasiran available to patients with familial chylomicronemia syndrome - New SHASTA-2 Phase 2 clinical data in patients with severe hypertriglyceridemia to be presented at ACC.24 Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR...
2024-03-20 18:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday. Shares of EQT Corporation (NYSE: EQT) fell sharply during...